Copyright Reports & Markets. All rights reserved.

Global Acute Myeloid Leukaemia Therapeutics Market 2026 by Company, Regions, Type and Application, Forecast to 2032

Request for Sample of this report
Buy now

1 Market Overview

  • 1.1 Product Overview and Scope
  • 1.2 Market Estimation Caveats and Base Year
  • 1.3 Classification of Acute Myeloid Leukaemia Therapeutics by Type
    • 1.3.1 Overview: Global Acute Myeloid Leukaemia Therapeutics Market Size by Type: 2021 Versus 2025 Versus 2032
    • 1.3.2 Global Acute Myeloid Leukaemia Therapeutics Consumption Value Market Share by Type in 2025
    • 1.3.3 Chemotherapy
    • 1.3.4 Targeted Therapy
    • 1.3.5 Immunotherapy
    • 1.3.6 Hypomethylating Agents
    • 1.3.7 Others
  • 1.4 Global Acute Myeloid Leukaemia Therapeutics Market by Application
    • 1.4.1 Overview: Global Acute Myeloid Leukaemia Therapeutics Market Size by Application: 2021 Versus 2025 Versus 2032
    • 1.4.2 Specialty Clinics
    • 1.4.3 Hospital
    • 1.4.4 Others
  • 1.5 Global Acute Myeloid Leukaemia Therapeutics Market Size & Forecast
  • 1.6 Global Acute Myeloid Leukaemia Therapeutics Market Size and Forecast by Region
    • 1.6.1 Global Acute Myeloid Leukaemia Therapeutics Market Size by Region: 2021 VS 2025 VS 2032
    • 1.6.2 Global Acute Myeloid Leukaemia Therapeutics Market Size by Region, (2021-2032)
    • 1.6.3 North America Acute Myeloid Leukaemia Therapeutics Market Size and Prospect (2021-2032)
    • 1.6.4 Europe Acute Myeloid Leukaemia Therapeutics Market Size and Prospect (2021-2032)
    • 1.6.5 Asia-Pacific Acute Myeloid Leukaemia Therapeutics Market Size and Prospect (2021-2032)
    • 1.6.6 South America Acute Myeloid Leukaemia Therapeutics Market Size and Prospect (2021-2032)
    • 1.6.7 Middle East & Africa Acute Myeloid Leukaemia Therapeutics Market Size and Prospect (2021-2032)

2 Company Profiles

  • 2.1 Pfizer Inc.
    • 2.1.1 Pfizer Inc. Details
    • 2.1.2 Pfizer Inc. Major Business
    • 2.1.3 Pfizer Inc. Acute Myeloid Leukaemia Therapeutics Product and Solutions
    • 2.1.4 Pfizer Inc. Acute Myeloid Leukaemia Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
    • 2.1.5 Pfizer Inc. Recent Developments and Future Plans
  • 2.2 Novartis AG
    • 2.2.1 Novartis AG Details
    • 2.2.2 Novartis AG Major Business
    • 2.2.3 Novartis AG Acute Myeloid Leukaemia Therapeutics Product and Solutions
    • 2.2.4 Novartis AG Acute Myeloid Leukaemia Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
    • 2.2.5 Novartis AG Recent Developments and Future Plans
  • 2.3 Celgene Corporation
    • 2.3.1 Celgene Corporation Details
    • 2.3.2 Celgene Corporation Major Business
    • 2.3.3 Celgene Corporation Acute Myeloid Leukaemia Therapeutics Product and Solutions
    • 2.3.4 Celgene Corporation Acute Myeloid Leukaemia Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
    • 2.3.5 Celgene Corporation Recent Developments and Future Plans
  • 2.4 Astellas Pharma Inc.
    • 2.4.1 Astellas Pharma Inc. Details
    • 2.4.2 Astellas Pharma Inc. Major Business
    • 2.4.3 Astellas Pharma Inc. Acute Myeloid Leukaemia Therapeutics Product and Solutions
    • 2.4.4 Astellas Pharma Inc. Acute Myeloid Leukaemia Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
    • 2.4.5 Astellas Pharma Inc. Recent Developments and Future Plans
  • 2.5 Daiichi Sankyo Company, Limited
    • 2.5.1 Daiichi Sankyo Company, Limited Details
    • 2.5.2 Daiichi Sankyo Company, Limited Major Business
    • 2.5.3 Daiichi Sankyo Company, Limited Acute Myeloid Leukaemia Therapeutics Product and Solutions
    • 2.5.4 Daiichi Sankyo Company, Limited Acute Myeloid Leukaemia Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
    • 2.5.5 Daiichi Sankyo Company, Limited Recent Developments and Future Plans
  • 2.6 Jazz Pharmaceuticals
    • 2.6.1 Jazz Pharmaceuticals Details
    • 2.6.2 Jazz Pharmaceuticals Major Business
    • 2.6.3 Jazz Pharmaceuticals Acute Myeloid Leukaemia Therapeutics Product and Solutions
    • 2.6.4 Jazz Pharmaceuticals Acute Myeloid Leukaemia Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
    • 2.6.5 Jazz Pharmaceuticals Recent Developments and Future Plans
  • 2.7 Boehringer Ingelheim International GmbH
    • 2.7.1 Boehringer Ingelheim International GmbH Details
    • 2.7.2 Boehringer Ingelheim International GmbH Major Business
    • 2.7.3 Boehringer Ingelheim International GmbH Acute Myeloid Leukaemia Therapeutics Product and Solutions
    • 2.7.4 Boehringer Ingelheim International GmbH Acute Myeloid Leukaemia Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
    • 2.7.5 Boehringer Ingelheim International GmbH Recent Developments and Future Plans
  • 2.8 Johnson & Johnson
    • 2.8.1 Johnson & Johnson Details
    • 2.8.2 Johnson & Johnson Major Business
    • 2.8.3 Johnson & Johnson Acute Myeloid Leukaemia Therapeutics Product and Solutions
    • 2.8.4 Johnson & Johnson Acute Myeloid Leukaemia Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
    • 2.8.5 Johnson & Johnson Recent Developments and Future Plans
  • 2.9 Gilead Sciences, Inc.
    • 2.9.1 Gilead Sciences, Inc. Details
    • 2.9.2 Gilead Sciences, Inc. Major Business
    • 2.9.3 Gilead Sciences, Inc. Acute Myeloid Leukaemia Therapeutics Product and Solutions
    • 2.9.4 Gilead Sciences, Inc. Acute Myeloid Leukaemia Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
    • 2.9.5 Gilead Sciences, Inc. Recent Developments and Future Plans
  • 2.10 Amgen Inc.
    • 2.10.1 Amgen Inc. Details
    • 2.10.2 Amgen Inc. Major Business
    • 2.10.3 Amgen Inc. Acute Myeloid Leukaemia Therapeutics Product and Solutions
    • 2.10.4 Amgen Inc. Acute Myeloid Leukaemia Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
    • 2.10.5 Amgen Inc. Recent Developments and Future Plans
  • 2.11 Takeda Pharmaceutical Company Limited
    • 2.11.1 Takeda Pharmaceutical Company Limited Details
    • 2.11.2 Takeda Pharmaceutical Company Limited Major Business
    • 2.11.3 Takeda Pharmaceutical Company Limited Acute Myeloid Leukaemia Therapeutics Product and Solutions
    • 2.11.4 Takeda Pharmaceutical Company Limited Acute Myeloid Leukaemia Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
    • 2.11.5 Takeda Pharmaceutical Company Limited Recent Developments and Future Plans
  • 2.12 Sunesis Pharmaceuticals, Inc.
    • 2.12.1 Sunesis Pharmaceuticals, Inc. Details
    • 2.12.2 Sunesis Pharmaceuticals, Inc. Major Business
    • 2.12.3 Sunesis Pharmaceuticals, Inc. Acute Myeloid Leukaemia Therapeutics Product and Solutions
    • 2.12.4 Sunesis Pharmaceuticals, Inc. Acute Myeloid Leukaemia Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
    • 2.12.5 Sunesis Pharmaceuticals, Inc. Recent Developments and Future Plans
  • 2.13 Agios Pharmaceuticals, Inc.
    • 2.13.1 Agios Pharmaceuticals, Inc. Details
    • 2.13.2 Agios Pharmaceuticals, Inc. Major Business
    • 2.13.3 Agios Pharmaceuticals, Inc. Acute Myeloid Leukaemia Therapeutics Product and Solutions
    • 2.13.4 Agios Pharmaceuticals, Inc. Acute Myeloid Leukaemia Therapeutics Revenue, Gross Margin and Market Share (2021-2026)
    • 2.13.5 Agios Pharmaceuticals, Inc. Recent Developments and Future Plans

3 Market Competition, by Players

  • 3.1 Global Acute Myeloid Leukaemia Therapeutics Revenue and Share by Players (2021-2026)
  • 3.2 Market Share Analysis (2025)
    • 3.2.1 Market Share of Acute Myeloid Leukaemia Therapeutics by Company Revenue
    • 3.2.2 Top 3 Acute Myeloid Leukaemia Therapeutics Players Market Share in 2025
    • 3.2.3 Top 6 Acute Myeloid Leukaemia Therapeutics Players Market Share in 2025
  • 3.3 Acute Myeloid Leukaemia Therapeutics Market: Overall Company Footprint Analysis
    • 3.3.1 Acute Myeloid Leukaemia Therapeutics Market: Region Footprint
    • 3.3.2 Acute Myeloid Leukaemia Therapeutics Market: Company Product Type Footprint
    • 3.3.3 Acute Myeloid Leukaemia Therapeutics Market: Company Product Application Footprint
  • 3.4 New Market Entrants and Barriers to Market Entry
  • 3.5 Mergers, Acquisition, Agreements, and Collaborations

4 Market Size Segment by Type

  • 4.1 Global Acute Myeloid Leukaemia Therapeutics Consumption Value and Market Share by Type (2021-2026)
  • 4.2 Global Acute Myeloid Leukaemia Therapeutics Market Forecast by Type (2027-2032)

5 Market Size Segment by Application

  • 5.1 Global Acute Myeloid Leukaemia Therapeutics Consumption Value Market Share by Application (2021-2026)
  • 5.2 Global Acute Myeloid Leukaemia Therapeutics Market Forecast by Application (2027-2032)

6 North America

  • 6.1 North America Acute Myeloid Leukaemia Therapeutics Consumption Value by Type (2021-2032)
  • 6.2 North America Acute Myeloid Leukaemia Therapeutics Market Size by Application (2021-2032)
  • 6.3 North America Acute Myeloid Leukaemia Therapeutics Market Size by Country
    • 6.3.1 North America Acute Myeloid Leukaemia Therapeutics Consumption Value by Country (2021-2032)
    • 6.3.2 United States Acute Myeloid Leukaemia Therapeutics Market Size and Forecast (2021-2032)
    • 6.3.3 Canada Acute Myeloid Leukaemia Therapeutics Market Size and Forecast (2021-2032)
    • 6.3.4 Mexico Acute Myeloid Leukaemia Therapeutics Market Size and Forecast (2021-2032)

7 Europe

  • 7.1 Europe Acute Myeloid Leukaemia Therapeutics Consumption Value by Type (2021-2032)
  • 7.2 Europe Acute Myeloid Leukaemia Therapeutics Consumption Value by Application (2021-2032)
  • 7.3 Europe Acute Myeloid Leukaemia Therapeutics Market Size by Country
    • 7.3.1 Europe Acute Myeloid Leukaemia Therapeutics Consumption Value by Country (2021-2032)
    • 7.3.2 Germany Acute Myeloid Leukaemia Therapeutics Market Size and Forecast (2021-2032)
    • 7.3.3 France Acute Myeloid Leukaemia Therapeutics Market Size and Forecast (2021-2032)
    • 7.3.4 United Kingdom Acute Myeloid Leukaemia Therapeutics Market Size and Forecast (2021-2032)
    • 7.3.5 Russia Acute Myeloid Leukaemia Therapeutics Market Size and Forecast (2021-2032)
    • 7.3.6 Italy Acute Myeloid Leukaemia Therapeutics Market Size and Forecast (2021-2032)

8 Asia-Pacific

  • 8.1 Asia-Pacific Acute Myeloid Leukaemia Therapeutics Consumption Value by Type (2021-2032)
  • 8.2 Asia-Pacific Acute Myeloid Leukaemia Therapeutics Consumption Value by Application (2021-2032)
  • 8.3 Asia-Pacific Acute Myeloid Leukaemia Therapeutics Market Size by Region
    • 8.3.1 Asia-Pacific Acute Myeloid Leukaemia Therapeutics Consumption Value by Region (2021-2032)
    • 8.3.2 China Acute Myeloid Leukaemia Therapeutics Market Size and Forecast (2021-2032)
    • 8.3.3 Japan Acute Myeloid Leukaemia Therapeutics Market Size and Forecast (2021-2032)
    • 8.3.4 South Korea Acute Myeloid Leukaemia Therapeutics Market Size and Forecast (2021-2032)
    • 8.3.5 India Acute Myeloid Leukaemia Therapeutics Market Size and Forecast (2021-2032)
    • 8.3.6 Southeast Asia Acute Myeloid Leukaemia Therapeutics Market Size and Forecast (2021-2032)
    • 8.3.7 Australia Acute Myeloid Leukaemia Therapeutics Market Size and Forecast (2021-2032)

9 South America

  • 9.1 South America Acute Myeloid Leukaemia Therapeutics Consumption Value by Type (2021-2032)
  • 9.2 South America Acute Myeloid Leukaemia Therapeutics Consumption Value by Application (2021-2032)
  • 9.3 South America Acute Myeloid Leukaemia Therapeutics Market Size by Country
    • 9.3.1 South America Acute Myeloid Leukaemia Therapeutics Consumption Value by Country (2021-2032)
    • 9.3.2 Brazil Acute Myeloid Leukaemia Therapeutics Market Size and Forecast (2021-2032)
    • 9.3.3 Argentina Acute Myeloid Leukaemia Therapeutics Market Size and Forecast (2021-2032)

10 Middle East & Africa

  • 10.1 Middle East & Africa Acute Myeloid Leukaemia Therapeutics Consumption Value by Type (2021-2032)
  • 10.2 Middle East & Africa Acute Myeloid Leukaemia Therapeutics Consumption Value by Application (2021-2032)
  • 10.3 Middle East & Africa Acute Myeloid Leukaemia Therapeutics Market Size by Country
    • 10.3.1 Middle East & Africa Acute Myeloid Leukaemia Therapeutics Consumption Value by Country (2021-2032)
    • 10.3.2 Turkey Acute Myeloid Leukaemia Therapeutics Market Size and Forecast (2021-2032)
    • 10.3.3 Saudi Arabia Acute Myeloid Leukaemia Therapeutics Market Size and Forecast (2021-2032)
    • 10.3.4 UAE Acute Myeloid Leukaemia Therapeutics Market Size and Forecast (2021-2032)

11 Market Dynamics

  • 11.1 Acute Myeloid Leukaemia Therapeutics Market Drivers
  • 11.2 Acute Myeloid Leukaemia Therapeutics Market Restraints
  • 11.3 Acute Myeloid Leukaemia Therapeutics Trends Analysis
  • 11.4 Porters Five Forces Analysis
    • 11.4.1 Threat of New Entrants
    • 11.4.2 Bargaining Power of Suppliers
    • 11.4.3 Bargaining Power of Buyers
    • 11.4.4 Threat of Substitutes
    • 11.4.5 Competitive Rivalry

12 Industry Chain Analysis

  • 12.1 Acute Myeloid Leukaemia Therapeutics Industry Chain
  • 12.2 Acute Myeloid Leukaemia Therapeutics Upstream Analysis
  • 12.3 Acute Myeloid Leukaemia Therapeutics Midstream Analysis
  • 12.4 Acute Myeloid Leukaemia Therapeutics Downstream Analysis

13 Research Findings and Conclusion

    14 Appendix

    • 14.1 Methodology
    • 14.2 Research Process and Data Source

    According to our (Global Info Research) latest study, the global Acute Myeloid Leukaemia Therapeutics market size was valued at US$ 4791 million in 2025 and is forecast to a readjusted size of US$ 9536 million by 2032 with a CAGR of 10.4% during review period.
    This report is a detailed and comprehensive analysis for global Acute Myeloid Leukaemia Therapeutics market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
    Key Features:
    Global Acute Myeloid Leukaemia Therapeutics market size and forecasts, in consumption value ($ Million), 2021-2032
    Global Acute Myeloid Leukaemia Therapeutics market size and forecasts by region and country, in consumption value ($ Million), 2021-2032
    Global Acute Myeloid Leukaemia Therapeutics market size and forecasts, by Type and by Application, in consumption value ($ Million), 2021-2032
    Global Acute Myeloid Leukaemia Therapeutics market shares of main players, in revenue ($ Million), 2021-2026
    The Primary Objectives in This Report Are:
    To determine the size of the total market opportunity of global and key countries
    To assess the growth potential for Acute Myeloid Leukaemia Therapeutics
    To forecast future growth in each product and end-use market
    To assess competitive factors affecting the marketplace
    This report profiles key players in the global Acute Myeloid Leukaemia Therapeutics market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Pfizer Inc., Novartis AG, Celgene Corporation, Astellas Pharma Inc., Daiichi Sankyo Company, Limited, Jazz Pharmaceuticals, Boehringer Ingelheim International GmbH, Johnson & Johnson, Gilead Sciences, Inc., Amgen Inc., etc.
    This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
    Market segmentation
    Acute Myeloid Leukaemia Therapeutics market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
    Market segment by Type
    Chemotherapy
    Targeted Therapy
    Immunotherapy
    Hypomethylating Agents
    Others
    Market segment by Application
    Specialty Clinics
    Hospital
    Others
    Market segment by players, this report covers
    Pfizer Inc.
    Novartis AG
    Celgene Corporation
    Astellas Pharma Inc.
    Daiichi Sankyo Company, Limited
    Jazz Pharmaceuticals
    Boehringer Ingelheim International GmbH
    Johnson & Johnson
    Gilead Sciences, Inc.
    Amgen Inc.
    Takeda Pharmaceutical Company Limited
    Sunesis Pharmaceuticals, Inc.
    Agios Pharmaceuticals, Inc.
    Market segment by regions, regional analysis covers
    North America (United States, Canada and Mexico)
    Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
    Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)
    South America (Brazil, Rest of South America)
    Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
    The content of the study subjects, includes a total of 13 chapters:
    Chapter 1, to describe Acute Myeloid Leukaemia Therapeutics product scope, market overview, market estimation caveats and base year.
    Chapter 2, to profile the top players of Acute Myeloid Leukaemia Therapeutics, with revenue, gross margin, and global market share of Acute Myeloid Leukaemia Therapeutics from 2021 to 2026.
    Chapter 3, the Acute Myeloid Leukaemia Therapeutics competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.
    Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2021 to 2032.
    Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2021 to 2026.and Acute Myeloid Leukaemia Therapeutics market forecast, by regions, by Type and by Application, with consumption value, from 2027 to 2032.
    Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.
    Chapter 12, the key raw materials and key suppliers, and industry chain of Acute Myeloid Leukaemia Therapeutics.
    Chapter 13, to describe Acute Myeloid Leukaemia Therapeutics research findings and conclusion.

    Buy now